AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9794507 — intervention group
Group type: EXPERIMENTAL
Intervention: AUCs truncated at 72 hours (AUC(0-72))
Number of subjects: 2214
Study 9794507 — intervention group
Group type: COMPARATOR
Intervention: AUCs extrapolated to infinity (AUC(inf))
Number of subjects: 2214
Study 8775995 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anti‐gliadin IgG and anti‐endomysium IgA
Number of subjects: 88
Study 8775995 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anti‐gliadin IgG and anti‐endomysium IgA plus anti‐gliadin IgA
Number of subjects: 88
Study 8775995 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological screening
Number of subjects: 88
Study 8775995 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dietary treatment
Number of subjects: 88
Study 2692883 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 100 micrograms/nasal cavity morning and evening
Number of subjects: 10
Study 2692883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 922756 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU (100 mg/m2 orally every 6 weeks)
Number of subjects: 57
Study 922756 — intervention group
Group type: EXPERIMENTAL
Intervention: methyl-CCNU (150 mg/m2 orally every 6 weeks)
Number of subjects: 57
Study 31335757 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge preparation by individual nurses
Number of subjects: 29986
Study 27179543 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous chest compression CPR (CCC‐CPR)
Number of subjects: 15
Study 27179543 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR (30:2 compression to breath ratio)
Number of subjects: 15
Study 25693990 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback with grades
Number of subjects: 83
Study 25693990 — intervention group
Group type: COMPARATOR
Intervention: Feedback without grades
Number of subjects: 83
Study 24735100 — intervention group
Group type: EXPERIMENTAL
Intervention: Insuman (400 IU/mL)
Number of subjects: 169
Study 24735100 — intervention group
Group type: COMPARATOR
Intervention: Insuplant
Number of subjects: 169
Study 22398784 — intervention group
Group type: EXPERIMENTAL
Intervention: apixaban 5 mg orally
Number of subjects: 20
Study 22398784 — intervention group
Group type: EXPERIMENTAL
Intervention: enoxaparin 40 mg subcutaneously
Number of subjects: 20
Study 22398784 — intervention group
Group type: EXPERIMENTAL
Intervention: apixaban 5 mg and enoxaparin 40 mg concomitantly
Number of subjects: 20
Study 22398784 — intervention group
Group type: EXPERIMENTAL
Intervention: apixaban 5 mg followed 6 hours after by enoxaparin 40 mg
Number of subjects: 20
Study 19279320 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1b
Number of subjects: 75
Study 19279320 — intervention group
Group type: COMPARATOR
Intervention: GA
Number of subjects: 75
Study 17157264 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring
Number of subjects: 0
Study 17157264 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure
Number of subjects: 0
Study 17157264 — intervention group
Group type: COMPARATOR
Intervention: Cognitive restructuring and exposure
Number of subjects: 0
Study 15217657 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine (Group Ropi-7.5)
Number of subjects: 68
Study 15217657 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine (Group Ropi-10)
Number of subjects: 68
Study 15217657 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ropivacaine (Group Ropi-5)
Number of subjects: 68
Study 11576802 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction Education intervention for parents prior to IV insertion
Number of subjects: 44
Study 11576802 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 44
Study 9850403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal Quinimax (20 mg/kg, then 15 mg/kg every 8 h for 2 days)
Number of subjects: 76
Study 9850403 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Quinimax (8 mg/kg infused over 4 h every 8 h for 2 days)
Number of subjects: 76
Study 8003055 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.6 gm of omega 3
Number of subjects: 90
Study 8003055 — intervention group
Group type: COMPARATOR
Intervention: 1.3 gm of omega 3 + 3 gm of olive oil
Number of subjects: 90
Study 8003055 — intervention group
Group type: COMPARATOR
Intervention: 6 gm of olive oil
Number of subjects: 90
Study 29861076 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical treatment plus human albumin (HA) (40 g twice weekly for 2 weeks, then 40 g weekly for up to 18 months)
Number of subjects: 440
Study 29861076 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (SMT)
Number of subjects: 440
Study 29861076 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical treatment plus human albumin (HA)
Number of subjects: 440
Study 27542601 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete choice experiment (DCE) survey prior to surgery
Number of subjects: 132
Study 27542601 — intervention group
Group type: COMPARATOR
Intervention: Modified survey without DCE activity
Number of subjects: 132
Study 23942818 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser therapy (EVLT)
Number of subjects: 65
Study 23942818 — intervention group
Group type: COMPARATOR
Intervention: High ligation of saphenous vein (HLS)
Number of subjects: 65
Study 23106506 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine bone grafting
Number of subjects: 40
Study 23106506 — intervention group
Group type: COMPARATOR
Intervention: No grafting material (Control)
Number of subjects: 40
Study 20418309 — intervention group
Group type: EXPERIMENTAL
Intervention: Central placement of local anesthetic (posterior cord)
Number of subjects: 218
Study 20418309 — intervention group
Group type: COMPARATOR
Intervention: Peripheral placement of local anesthetic (medial or lateral cord)
Number of subjects: 218
Study 17986497 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise group
Number of subjects: 64
Study 17986497 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercise group
Number of subjects: 64
Study 16598777 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 0.5 mg bid
Number of subjects: 119
Study 16598777 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.0 mg bid
Number of subjects: 119
Study 16598777 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 2 mg bid
Number of subjects: 119
Study 16598777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 14598248 — intervention group
Group type: EXPERIMENTAL
Intervention: hospital‐based computer‐assisted sphincter pressure biofeedback
Number of subjects: 171
Study 14598248 — intervention group
Group type: COMPARATOR
Intervention: standard care (advice)
Number of subjects: 171
Study 14598248 — intervention group
Group type: EXPERIMENTAL
Intervention: hospital biofeedback plus the use of a home electromyelogram biofeedback device
Number of subjects: 171
Study 14598248 — intervention group
Group type: EXPERIMENTAL
Intervention: advice plus instruction on sphincter exercises
Number of subjects: 171
Study 11095338 — intervention group
Group type: EXPERIMENTAL
Intervention: Manning criteria
Number of subjects: 4500
Study 11095338 — intervention group
Group type: EXPERIMENTAL
Intervention: Rome I criteria
Number of subjects: 4500
Study 11095338 — intervention group
Group type: EXPERIMENTAL
Intervention: Rome II criteria
Number of subjects: 4500
Study 11095338 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS regardless of criteria
Number of subjects: 4500
Study 11095338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and bowel habit severity
Number of subjects: 4500
Study 8971430 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg administered orally after a standard breakfast
Number of subjects: 17
Study 8971430 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide 2 mg administered orally after a standard breakfast
Number of subjects: 17
Study 1346172 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone (2.5 mg twice a week for 3 months)
Number of subjects: 145
Study 1346172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 1346172 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone
Number of subjects: 145
Study 6231104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 48
Study 6231104 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 48
Study 29594933 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling option (individualized CHW-led education with choice of HPV self-sampling or CHW-facilitated navigation to Pap smear)
Number of subjects: 601
Study 29594933 — intervention group
Group type: COMPARATOR
Intervention: Outreach (outreach by CHWs and provision of culturally tailored cervical cancer screening information)
Number of subjects: 601
Study 29594933 — intervention group
Group type: COMPARATOR
Intervention: Navigation (individualized CHW-led education and navigation to local health care facilities for Pap smear)
Number of subjects: 601
Study 27743701 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOPA‐COG at baseline and year 5
Number of subjects: 1741
Study 27743701 — intervention group
Group type: EXPERIMENTAL
Intervention: SDMT annually
Number of subjects: 1741
Study 24373681 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 244
Study 24373681 — intervention group
Group type: COMPARATOR
Intervention: Control (no physical therapy)
Number of subjects: 244
Study 24382182 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal occlusal appliance device (PG)
Number of subjects: 50
Study 24382182 — intervention group
Group type: COMPARATOR
Intervention: Control group without any treatment (CG)
Number of subjects: 50
Study 20860092 — intervention group
Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CT-CA)
Number of subjects: 44
Study 20860092 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 44
Study 19695404 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of glucosamine sulfate 500 mg
Number of subjects: 22
Study 19695404 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of glucosamine sulfate 500 mg
Number of subjects: 22
Study 15842277 — intervention group
Group type: COMPARATOR
Intervention: Cannula aspiration (CA)
Number of subjects: 200
Study 15842277 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy forceps (BF)
Number of subjects: 200
Study 12611766 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP)
Number of subjects: 6
Study 12611766 — intervention group
Group type: COMPARATOR
Intervention: No LBPP (control)
Number of subjects: 6
Study 10596845 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol/alfentanil
Number of subjects: 36
Study 10596845 — intervention group
Group type: COMPARATOR
Intervention: midazolam/fentanyl
Number of subjects: 36
Study 8732695 — intervention group
Group type: EXPERIMENTAL
Intervention: Perilymphatic injections of recombinant interleukin-2 (rIL-2)
Number of subjects: 60
Study 8732695 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery only)
Number of subjects: 60
Study 1878176 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG feedback
Number of subjects: 24
Study 1878176 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 24
Study 6139669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 75
Study 6139669 — intervention group
Group type: COMPARATOR
Intervention: Control medical management
Number of subjects: 75
Study 27956477 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing comfort foods (food image)
Number of subjects: 60
Study 27956477 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing comfort foods (food art)
Number of subjects: 60
Study 27956477 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing fruits (food image)
Number of subjects: 60
Study 27956477 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing fruits (food art)
Number of subjects: 60
Study 27956477 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing comfort foods (food image) for those with clinical symptoms of depression
Number of subjects: 60
Study 27956477 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing comfort foods (food art) for those with clinical symptoms of depression
Number of subjects: 60
Study 27502850 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months DAPT
Number of subjects: 1500
Study 27502850 — intervention group
Group type: COMPARATOR
Intervention: 12 months DAPT
Number of subjects: 1500
Study 24807871 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (OMP)
Number of subjects: 90
Study 24807871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 22808716 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of emotions by manipulating height
Number of subjects: 14
Study 22808716 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional and dysfunctional emotions measured during routines
Number of subjects: 14
Study 20697803 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/day for 14 days
Number of subjects: 25
Study 20697803 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 25
Study 20697803 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 25
Study 18318083 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 0
Study 18318083 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 17038256 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) given after tissue oxygenation indicated by PiCO(2) normalization
Number of subjects: 96
Study 17038256 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition (EN) given at the early stage of recovery from shock (control group)
Number of subjects: 96
Study 17038256 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received enteral nutrition
Number of subjects: 96
Study 14633547 — intervention group
Group type: EXPERIMENTAL
Intervention: IT morphine 100 microg
Number of subjects: 60
Study 14633547 — intervention group
Group type: EXPERIMENTAL
Intervention: IT morphine 200 microg
Number of subjects: 60
Study 14633547 — intervention group
Group type: EXPERIMENTAL
Intervention: IT morphine 50 microg
Number of subjects: 60
Study 14633547 — intervention group
Group type: COMPARATOR
Intervention: IT morphine 0 microg
Number of subjects: 60
Study 14633547 — intervention group
Group type: EXPERIMENTAL
Intervention: IT morphine 100 microg vs 200 microg
Number of subjects: 60
Study 14633547 — intervention group
Group type: EXPERIMENTAL
Intervention: IT morphine 100 microg vs 50 microg vs 200 microg
Number of subjects: 60
Study 10677051 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate formulas
Number of subjects: 22
Study 10677051 — intervention group
Group type: COMPARATOR
Intervention: Whey and milk protein challenges
Number of subjects: 22
Study 9058336 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen barrier material
Number of subjects: 10
Study 9058336 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene barrier material
Number of subjects: 10
Study 9058336 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactic acid barrier material
Number of subjects: 10
Study 9058336 — intervention group
Group type: COMPARATOR
Intervention: Control site (natural colonization of the tooth surface)
Number of subjects: 10
Study 8393359 — intervention group
Group type: EXPERIMENTAL
Intervention: oral alkali therapy with sodium bicarbonate 2 mmol/kg/day
Number of subjects: 170
Study 8393359 — intervention group
Group type: COMPARATOR
Intervention: no therapy (control group)
Number of subjects: 170
Study 3105242 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 30
Study 3105242 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 30
Study 3105242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29301639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Number of subjects: 0
Study 25645978 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 16
Study 25645978 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 16
Study 25645978 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT
Number of subjects: 16
Study 25645978 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT
Number of subjects: 16
Study 24685998 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (church-based health program)
Number of subjects: 221
Study 24685998 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 221
Study 22719932 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid antivenom infusion (20 minute infusion)
Number of subjects: 104
Study 22719932 — intervention group
Group type: COMPARATOR
Intervention: Slow antivenom infusion (2 hour infusion)
Number of subjects: 104
Study 22719932 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid antivenom infusion
Number of subjects: 104
Study 22719932 — intervention group
Group type: COMPARATOR
Intervention: Slow antivenom infusion
Number of subjects: 104
Study 19833214 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/d)
Number of subjects: 18
Study 19833214 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/d)
Number of subjects: 18
Study 19833214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19833214 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram and Citalopram
Number of subjects: 18
Study 18032762 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 351
Study 18032762 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus dexamethasone
Number of subjects: 351
Study 16134010 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately intoxicating alcohol dose
Number of subjects: 44
Study 16134010 — intervention group
Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 44
Study 11939442 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.5 mg/kg
Number of subjects: 63
Study 11939442 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 15 mg/kg
Number of subjects: 63
Study 10516877 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (1‐amino 3,5‐dimethyl‐adamantane hydrochloride)
Number of subjects: 12
Study 10516877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7627863 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal coronary angiography
Number of subjects: 45
Study 7627863 — intervention group
Group type: COMPARATOR
Intervention: Pathological coronary angiography
Number of subjects: 45
Study 2032518 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 309
Study 2032518 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice a day
Number of subjects: 309
Study 7137662 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (10 mg)
Number of subjects: 27
Study 7137662 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (15 mg)
Number of subjects: 27
Study 30217513 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac Ganglia Neurolysis (CGN)
Number of subjects: 110
Study 30217513 — intervention group
Group type: COMPARATOR
Intervention: Celiac Plexus Neurolysis (CPN)
Number of subjects: 110
Study 28218551 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical protocol A
Number of subjects: 448
Study 28218551 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical protocol B
Number of subjects: 448
Study 28218551 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical protocol C
Number of subjects: 448
Study 28218551 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical protocol D
Number of subjects: 448
Study 24446238 — intervention group
Group type: EXPERIMENTAL
Intervention: Assist control mode with 6 mL/kg tidal volume and constant flow 60 L/min
Number of subjects: 20
Study 24446238 — intervention group
Group type: EXPERIMENTAL
Intervention: Assist control mode with 8 mL/kg tidal volume and decelerating flow 40 L/min
Number of subjects: 20
Study 24446238 — intervention group
Group type: EXPERIMENTAL
Intervention: Various ventilator settings (assist control and pressure support)
Number of subjects: 20
Study 24446238 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic variables recorded during varying ventilator settings
Number of subjects: 20
Study 24446238 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort level measured using a 10-point Borg scale
Number of subjects: 20
Study 24956001 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive messaging
Number of subjects: 0
Study 24956001 — intervention group
Group type: COMPARATOR
Intervention: Negative messaging
Number of subjects: 0
Study 24956001 — intervention group
Group type: COMPARATOR
Intervention: Neutral messaging
Number of subjects: 0
Study 24956001 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively-framed messages
Number of subjects: 0
Study 24956001 — intervention group
Group type: COMPARATOR
Intervention: Negatively-framed messages
Number of subjects: 0
Study 22866000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ricotta cheese (210 g/day) plus habitual diet
Number of subjects: 40
Study 22866000 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet with no additional intervention
Number of subjects: 40
Study 20431329 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gamma ventral capsulotomy
Number of subjects: 1
Study 20431329 — intervention group
Group type: COMPARATOR
Intervention: Sham radiosurgical procedure
Number of subjects: 1
Study 17353168 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine system for the transmission of morpho/immunological data
Number of subjects: 0
Study 15867104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (100 to 600 mg/d)
Number of subjects: 140
Study 15867104 — intervention group
Group type: EXPERIMENTAL
Intervention: CBASP (twice weekly for weeks 1-4, weekly thereafter)
Number of subjects: 140
Study 12419087 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (CEE) 0.625 mg daily
Number of subjects: 21